What does Lundbeck do?

Lundbeck, officially known as H. Lundbeck A/S, is a global biopharmaceutical company based in Valby, Copenhagen, Denmark. Founded in 1915, Lundbeck specializes in neuroscience, focusing exclusively on brain diseases. The company is publicly traded on the Copenhagen Stock Exchange and is majority-owned by the Lundbeck Foundation. Lundbeck operates in over 50 countries and employs approximately 5,600 people. It manages the entire drug development process, from research to commercialization, with production facilities in Denmark, France, and Italy. The company is dedicated to advancing brain health through innovative therapies for psychiatric and neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Its notable products include Rexulti for schizophrenia and Eptinezumab for migraine prevention. Lundbeck's commitment to improving patient lives is reflected in its extensive support programs and partnerships with healthcare providers worldwide.